Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio A Brausi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Thescientificworldjournal|July 11, 2007
New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladderMaurizio A Brausi
Urologic Oncology|December 22, 2014
World Urologic Oncology Federation Bladder Cancer Prevention Program: a global initiativeLaurence Klotz, Maurizio A Brausi
European Urology|June 2, 2009
Complications following radical cystectomy for bladder cancer in the elderlyMichael Froehner, Maurizio A Brausi, Harry W Herr, et al.
Urologia Internationalis|November 17, 2011
Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion studyMaurizio A Brausi, Paolo Gontero, Vincenzo Altieri, et al.
European Urology|May 18, 2007
Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survivalMaurizio A Brausi, Mirko Gavioli, Giuseppe De Luca, et al.
European Urology|May 18, 2007
The use of local anesthesia with N-DO injector (Physion) for transurethral resection (TUR) of bladder tumors and bladder mapping: preliminary results and cost-effectiveness analysisMaurizio A Brausi, Giorgio Verrini, Giuseppe De Luca, et al.
European Urology|September 11, 2012
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancerDavid R Yates, Maurizio A Brausi, James W F Catto, et al.
BJU International|March 7, 2016
Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911Jorg R Oddens, Richard J Sylvester, Maurizio A Brausi, et al.
European Urology|June 21, 2014
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911Jorg R Oddens, Richard J Sylvester, Maurizio A Brausi, et al.
European Urology|December 26, 2009
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladderRichard J Sylvester, Maurizio A Brausi, Wim J Kirkels, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Thescientificworldjournal|July 11, 2007
New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladderMaurizio A Brausi
Urologic Oncology|December 22, 2014
World Urologic Oncology Federation Bladder Cancer Prevention Program: a global initiativeLaurence Klotz, Maurizio A Brausi
European Urology|June 2, 2009
Complications following radical cystectomy for bladder cancer in the elderlyMichael Froehner, Maurizio A Brausi, Harry W Herr, et al.
Urologia Internationalis|November 17, 2011
Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion studyMaurizio A Brausi, Paolo Gontero, Vincenzo Altieri, et al.
European Urology|May 18, 2007
Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survivalMaurizio A Brausi, Mirko Gavioli, Giuseppe De Luca, et al.
European Urology|May 18, 2007
The use of local anesthesia with N-DO injector (Physion) for transurethral resection (TUR) of bladder tumors and bladder mapping: preliminary results and cost-effectiveness analysisMaurizio A Brausi, Giorgio Verrini, Giuseppe De Luca, et al.
European Urology|September 11, 2012
Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancerDavid R Yates, Maurizio A Brausi, James W F Catto, et al.
BJU International|March 7, 2016
Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guérin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911Jorg R Oddens, Richard J Sylvester, Maurizio A Brausi, et al.
European Urology|June 21, 2014
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911Jorg R Oddens, Richard J Sylvester, Maurizio A Brausi, et al.
European Urology|December 26, 2009
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladderRichard J Sylvester, Maurizio A Brausi, Wim J Kirkels, et al.
Pageof 2